DEVELOPMENT AND VALIDATION OF SPECTROPHOTOMETRIC METHODS FOR SIMULTANEOUS ESTIMATION OF OLANZAPINE AND FLUOXETINE FROM BULK AND TABLET DOSAGE FORM BY Q-ABSORBANCE RATIO METHOD

Depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite and poor concentration with anxiety. Olanzapine is a second-generation antipsychotic (SGA) or atypical antipsychotic. It has attracted considerable interests due to its wide range of therapeutic and pharmacological properties and works in the brain to treat schizophrenia disorder, and may also be used in bipolar disorder and Schizophrenia. Fluoxetine is a class of selective serotonin reuptake inhibitors (SSRI) and works by blocking the absorption of the neurotransmitter serotonin in the brain. Regulating the amount of serotonin helps brain cells transmit messages to each other. This results in a better and more stable mood. For development and validation of Spectrophotometric Methods for Simultaneous estimation of Olanzapine and Fluoxetine from Bulk and Tablet Dosage Form was used Q-Absorbance Ratio method. Using the double beam instrument of Shimadzu –UV1900, as UV/Visible spectrophotometer method developed for simultaneous estimation of Q-Absorbance Ratio method. For the Q-Absorbance Ratio method Olanzapine at 288 nm for Olanzapine (λ_max) and 232.5 nm (Isosbestic point) for Olanzapine and Fluoxetine, at 288 nm Fluoxetine showed zero absorbance, and at 288 nm Olanzapine showed significant absorbance. The developed methods can be successfully applied for the determination of the amount of drugs present in tablet formulation.